(GMRE) Global Medical REIT - Ratings and Ratios
Acute, Post-Acute, Behavioral, Rehabilitation, Seniors
GMRE EPS (Earnings per Share)
GMRE Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 28.4% |
| Value at Risk 5%th | 44.6% |
| Reward | |
|---|---|
| Sharpe Ratio | -0.65 |
| Alpha | -37.93 |
| Character | |
|---|---|
| Hurst Exponent | 0.628 |
| Beta | 1.210 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.20% |
| Mean DD | 18.06% |
Description: GMRE Global Medical REIT August 28, 2025
Global Medical REIT (GMRE) operates a portfolio of outpatient medical facilities across the United States, targeting high‑growth specialties such as orthopedics, cardiology, and imaging. The REIT’s revenue model is anchored in long‑term triple‑net leases with healthcare operators, delivering predictable cash flows and minimal landlord expense exposure.
Key performance indicators for GMRE include Funds From Operations (FFO) and Adjusted Funds From Operations (AFFO), which strip out depreciation and amortization to reflect true cash generation. Recent quarters have shown FFO growth in the low‑double‑digit range year‑over‑year, driven by rent escalations tied to CPI and strategic lease renewals at above‑market rates. AFFO, after accounting for capital expenditures and lease‑hold improvements, remains robust, supporting a dividend payout ratio comfortably above 80%.
Occupancy levels consistently exceed 95%, reflecting strong tenant demand and the REIT’s disciplined acquisition strategy that emphasizes properties in high‑income, aging demographics. The tenant base is diversified, with no single lessee accounting for more than 5% of total rent roll, mitigating concentration risk. Lease terms average 10–12 years with built‑in rent escalations, providing a stable income horizon.
Financial leverage is managed through a mix of senior secured debt and unsecured notes, resulting in a net debt‑to‑FFO ratio near 3.0×. The interest coverage ratio, measured as EBITDA divided by interest expense, stays above 4.0×, indicating ample capacity to service debt even under modest earnings volatility. The REIT’s dividend yield hovers around 7%, positioning it as an attractive income generator in a low‑interest‑rate environment.
Macro‑economic drivers influencing GMRE’s outlook include the continued expansion of the U.S. Medicare‑eligible population, increasing preference for outpatient over inpatient care, and favorable reimbursement trends. However, rising interest rates could pressure REIT valuations and increase borrowing costs, while regulatory changes in healthcare reimbursement could affect tenant profitability and, indirectly, rent growth.
GMRE Stock Overview
| Market Cap in USD | 881m |
| Sub-Industry | Health Care REITs |
| IPO / Inception | 2016-06-29 |
| Return 12m vs S&P 500 | -29.5% |
| Analyst Rating | 3.90 of 5 |
GMRE Dividends
| Dividend Yield | 10.97% |
| Yield on Cost 5y | 7.58% |
| Yield CAGR 5y | 1.23% |
| Payout Consistency | 97.3% |
| Payout Ratio | - |
GMRE Growth Ratios
| CAGR | -2.57% |
| CAGR/Max DD Calmar Ratio | -0.07 |
| CAGR/Mean DD Pain Ratio | -0.14 |
| Current Volume | 153.7k |
| Average Volume | 167.5k |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-1.87m TTM) > 0 and > 6% of Revenue (6% = 8.89m TTM) |
| FCFTA -0.04 (>2.0%) and ΔFCFTA -8.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -443.0% (prev -465.8%; Δ 22.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 71.2m > Net Income -1.87m (YES >=105%, WARN >=100%) |
| Net Debt (-7.12m) to EBITDA (42.9m) ratio: -0.17 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (13.4m) change vs 12m ago 408.9% (target <= -2.0% for YES) |
| Gross Margin 63.50% (prev 79.36%; Δ -15.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 11.78% (prev 10.98%; Δ 0.80pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.94 (EBITDA TTM 42.9m / Interest Expense TTM 30.9m) >= 6 (WARN >= 3) |
Altman Z'' -4.52
| (A) -0.52 = (Total Current Assets 15.1m - Total Current Liabilities 671.5m) / Total Assets 1.27b |
| (B) -0.26 = Retained Earnings (Balance) -332.6m / Total Assets 1.27b |
| (C) 0.02 = EBIT TTM 29.0m / Avg Total Assets 1.26b |
| (D) -0.42 = Book Value of Equity -325.1m / Total Liabilities 767.4m |
| Total Rating: -4.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.79
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -3.44% = -1.72 |
| 3. FCF Margin -35.41% = -7.50 |
| 4. Debt/Equity 1.35 = 1.66 |
| 5. Debt/Ebitda -0.17 = 2.50 |
| 6. ROIC - WACC (= -3.98)% = -4.98 |
| 7. RoE -0.37% = -0.06 |
| 8. Rev. Trend 25.55% = 1.92 |
| 9. EPS Trend -40.60% = -2.03 |
What is the price of GMRE shares?
Over the past week, the price has changed by +8.82%, over one month by +4.86%, over three months by +3.74% and over the past year by -18.55%.
Is Global Medical REIT a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GMRE is around 32.14 USD . This means that GMRE is currently overvalued and has a potential downside of -2.04%.
Is GMRE a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GMRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43.9 | 33.7% |
| Analysts Target Price | 43.9 | 33.7% |
| ValueRay Target Price | 35.2 | 7.3% |
GMRE Fundamental Data Overview November 10, 2025
P/E Forward = 232.5581
P/S = 6.0825
P/B = 1.0266
P/EG = -26.28
Beta = 1.21
Revenue TTM = 148.2m USD
EBIT TTM = 29.0m USD
EBITDA TTM = 42.9m USD
Long Term Debt = 14.4m USD (from longTermDebt, last fiscal year)
Short Term Debt = 631.7m USD (from shortTermDebt, last fiscal year)
Debt = 653.6m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -7.12m USD (from netDebt column, last quarter)
Enterprise Value = 1.53b USD (880.9m + Debt 653.6m - CCE 7.12m)
Interest Coverage Ratio = 0.94 (Ebit TTM 29.0m / Interest Expense TTM 30.9m)
FCF Yield = -3.44% (FCF TTM -52.5m / Enterprise Value 1.53b)
FCF Margin = -35.41% (FCF TTM -52.5m / Revenue TTM 148.2m)
Net Margin = -1.26% (Net Income TTM -1.87m / Revenue TTM 148.2m)
Gross Margin = 63.50% ((Revenue TTM 148.2m - Cost of Revenue TTM 54.1m) / Revenue TTM)
Gross Margin QoQ = 57.68% (prev 43.04%)
Tobins Q-Ratio = 1.20 (Enterprise Value 1.53b / Total Assets 1.27b)
Interest Expense / Debt = 1.25% (Interest Expense 8.18m / Debt 653.6m)
Taxrate = 1.20% (-108.0k / -9.02m)
NOPAT = 28.7m (EBIT 29.0m * (1 - 1.20%))
Current Ratio = 0.02 (Total Current Assets 15.1m / Total Current Liabilities 671.5m)
Debt / Equity = 1.35 (Debt 653.6m / totalStockholderEquity, last quarter 485.3m)
Debt / EBITDA = -0.17 (Net Debt -7.12m / EBITDA 42.9m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -7.12m / FCF TTM -52.5m)
Total Stockholder Equity = 510.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.15% (Net Income -1.87m / Total Assets 1.27b)
RoE = -0.37% (Net Income TTM -1.87m / Total Stockholder Equity 510.0m)
RoCE = 5.53% (EBIT 29.0m / Capital Employed (Equity 510.0m + L.T.Debt 14.4m))
RoIC = 2.55% (NOPAT 28.7m / Invested Capital 1.12b)
WACC = 6.54% (E(880.9m)/V(1.53b) * Re(10.47%) + D(653.6m)/V(1.53b) * Rd(1.25%) * (1-Tc(0.01)))
Discount Rate = 10.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 125.9%
Fair Price DCF = unknown (Cash Flow -52.5m)
EPS Correlation: -40.60 | EPS CAGR: -7.04% | SUE: -0.07 | # QB: 0
Revenue Correlation: 25.55 | Revenue CAGR: 1.03% | SUE: -0.33 | # QB: 0
Additional Sources for GMRE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle